Clinical Trials
30 trialsTislelizumab Plus FOLFOX Versus POF in the Treatment of Locally Advanced: a Multicenter, Open-label, Randomized Phase III Studyunresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma
Fujian Cancer Hospital
LEDANG
Hospital Sultanah Bahiyah
Evaluation of TRANSKRIP ® Plus Chemotherapy in Recurrent-Persistent Cervical Cancer
National Institute of Cancerología
Phase I/II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab
Fujian Cancer Hospital
ACCESS-I
Instituto Nacional de Cancer, Brazil
Tislelizumab Combined With Chemotherapy or Radiotherapy in the Treatment of Advanced or Recurrent Metastatic Elderly Esophageal Cancer
Fujian Cancer Hospital
First-line Gemcitabine Plus Cisplatin in Locally Advanced (IIIC Stage) Breast Cancer Patients
The National Center of Oncology, Azerbaijan
Cadonilimab (AK104) Plus Chemotherapy in Patients With Recurrent or Advanced Endometrial Cancer
Fujian Cancer Hospital
SMET12 and Toripalimab Combined Chemotherapy in Patients With EGFR Positive Advanced Non-small Cell Lung Cancer (NSCLC)
Fujian Cancer Hospital
Phase II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab in Advanced Gastric Cancer
Fujian Cancer Hospital
Clinical Study of Adebrelimab Combined With Concurrent Chemoradiotherapy in Cervical Cancer
Fujian Cancer Hospital
Artemis
National Cancer Center, Japan
Tislelizumab Combined With Chemotherapy in the Cross-line Treatment of First-line Resistant Advanced Gastric Cancer
Fujian Cancer Hospital
Neoadjuvant Chemotherapy Compared With Surgery for Esophageal Carcinoma
Henan Cancer Hospital
Paclitaxel and DDP Combined With Anlotinib in the First-line Treatment for Patients With Advanced Esophageal Squamous Cell Carcinoma(ESCC).
Henan Cancer Hospital
TQB2450 Solution for Injection (TQB2450)+Paclitaxel+Cisplatin ± Anlotinib in the Treatment of Esophageal Cancer.
Henan Cancer Hospital
TIP
National Cancer Institute, Slovakia
SCOPE2
Velindre NHS Trust
QUIMERA
Instituto Nacional de Cancer, Brazil
mFOLFOX Versus mFOLFIRI Versus FOLFPTX as First-line Treatment in AGC or EGJA
Fujian Cancer Hospital
NeoSCOPE
Velindre NHS Trust
ICON8
Medical Research Council
PGH
National Cancer Center, Korea
PGS
National Cancer Center, Korea
PGT
National Cancer Center, Korea
Genexol-PM Versus Paclitaxel in Anthracycline-pretreated Metastatic Breast Cancer Patients
National Cancer Center, Korea
Concurrent Chemoradiotherapy (CCRT) With Paclitaxel Plus Cisplatin in LA Non-small-cell Lung Cancer (NSCLC)
Taipei Veterans General Hospital, Taiwan
Primary Paclitaxel Plus Gemcitabine in Patients With Stage II and III Breast Cancer
National Cancer Center, Korea
Weekly Paclitaxel Plus Gemcitabine as Second-line in Small Cell Lung Cancer
National Cancer Center, Korea
Paclitaxel and Capecitabine in Patients With Metastatic/Recurrence Esophageal Cancer
National Cancer Center, Korea